NephrosNEPH
Recorded

Nephros 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration33 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

I'll now turn the call over to Kirin Smith.

Kirin SmithPresident

You may begin. Thank you, everyone, and good afternoon.

Kirin SmithPresident

This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros' third quarter 2026 conference call. Before we begin, I would like to caution that comments made during this conference call made by management will contain forward-looking statements regarding the operations and future results of Nephros. I encourage you to review Nephros' filings with the Securities and Exchange Commission, including without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Kirin SmithPresident

Factors that may affect the company's results include, but are not limited to, Nephros' ability to successfully, timely, and cost-effectively market and sell its products and service offerings, the rate of adoption of its products and services by hospitals and other healthcare providers, the success of its commercialization efforts, and the effect of existing and new regulatory requirements on Nephros' business and other economic and competitive factors. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, November 6, 2026. The company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. I would now like to turn the call over to Nephros' President and Chief Executive Officer, Robert Banks.

Robert BanksPresident and CEO

Robert, please go ahead. Thank you, Kirin, and good afternoon, everyone.

Robert BanksPresident and CEO

The third quarter of 2026 was another strong quarter for Nephros, and more importantly, provides additional evidence of the durability of the growth we have been building over the last several years. We generated approximately $5.6 million in revenue, an increase of 18% over the third quarter of 2025. This followed the record $6 million we reported in the second quarter. I think that sequence is important. A record quarter is exciting. Following a record quarter with another quarter of strong double-digit year-over-year growth tells us much more about the underlying business. For the first nine months of 2026, revenue reached approximately $15.9 million, an increase of 20% over the same period last year. Core programmatic revenue increased 19% over that nine-month period.

Robert BanksPresident and CEO

Importantly, this is profitable revenue growth where net income and adjusted EBITDA increased respectively to approximately $500,000 and approximately $600,000. Our trailing 12-month revenue has now surpassed $21 million. When you look at those results together, I believe they demonstrate that Nephros is becoming a larger, stronger, and increasingly durable business. Our core programmatic business remains the foundation of that growth. Programmatic product revenue increased approximately 8% during the third quarter compared with last year. That business is particularly important to us because it represents customers incorporating Nephros products into their operations and then purchasing replacement filters over time. Every new installation has the potential to contribute to future recurring demand. Emergency response also contributed meaningfully during the quarter. As we have discussed several times, emergency response will fluctuate depending on outbreaks, infrastructure issues, and other urgent water quality events.

Robert BanksPresident and CEO

We don't build our long-term growth strategy around emergencies, but the ability to respond quickly when customers need us remains an important part of what differentiates Nephros. Service revenue also continued to grow. We increasingly see customers looking to Nephros not only to provide filtration products, but to also help install them, replace them, and support the filtration component of the broader water management programs. That brings me to another encouraging indicator from the quarter, the continued expansion of our customer base. We ended Q3 with a record 1,766 active customer sites, having added approximately 31 in Q3 alone. Healthcare remains at the center of Nephros, representing 64% of new sites added during the quarter. But we are also seeing the technology find applications outside of our traditional healthcare business.

Robert BanksPresident and CEO

Approximately 17% of new sites came from commercial and industrial customers, with the remainder representing government, military, hospitality, residential, retail, and other applications. I believe that diversification is important. Our objective is to not move away from healthcare, because healthcare remains our largest market and an area we believe substantial opportunity remains. Instead, we are taking the technology, expertise, and reputation we have built in a demanding healthcare environment and identifying additional applications where water quality matters. We continue to monitor emerging industry standards, regulatory developments, and market intelligence to unmet needs and determine where Nephros technology can provide meaningful value. That approach has already helped us expand our product portfolio into applications involving sterile processing, PFAS, microplastics, and nanoplastics, as well as drinking water, commercial filtration, and other emerging water quality challenges. At the same time, our strategy continues to evolve beyond products alone.

Robert BanksPresident and CEO

We've talked previously about the three pillars we are building around Nephros: products, service, education. Products remains the foundation. Service makes these products easier for customers to adopt and maintain, and education is increasingly helping us create relationships earlier in the decision-making process. During the third quarter, the Nephros Water Institute continued a strong series of educational webinars addressing water quality issues relevant to healthcare professionals and other customers. We believe this is becoming an increasingly important part of our commercial strategy. Education allows us to engage customers and industry professionals around emerging water quality challenges, share expertise we have accumulated over many years, and build relationships well before someone is ready to make a filtration decision. Our goal isn't simply to conduct webinars. The goal is to make Nephros a trusted resource for water quality information.

Robert BanksPresident and CEO

When we educate the market effectively, we increase awareness of water safety challenges and potential solutions. That creates engagement, generates qualified opportunities, and helps support product and service adoption over time. We therefore expect to continue investing in education as a driver of market development and commercial growth. Before turning the call over to Judy, I also want to address profitability and margins. Gross margin was approximately 58% in the third quarter compared with 61% in the prior year period. As we have discussed on previous calls, several factors continue to affect margins, including shipping and handling costs, tariffs, and changes in revenue mix. Service is a good example of the trade-off involved. Service currently carries a lower gross margin percentage than our traditional infection control product business, but it generates incremental gross profit dollars, supports product sales, and removes barriers to adoption, and can deepen customer relationships.

Robert BanksPresident and CEO

We continue to evaluate the business based not simply on maximizing a quarterly gross margin percentage, but also on creating sustainable, profitable growth. We remain focused on pricing, sourcing, freight, product mix, and operational efficiency, while continuing to invest where we believe these investments can create attractive long-term returns. Overall, I am very pleased with where we stand after nine months. Revenue is up 20%. Core programmatic revenue is up 19%. We increased our profitability. Our active customer sites have hit a record high level, which is very important because we've talked about that over and over again. Our service capabilities continue to expand. Our educational strategy is gaining momentum, and we continue to identify new applications for Nephros technology. There is considerable work still ahead of us, but I believe we are entering the final quarter of 2026 from a position of strength.

Robert BanksPresident and CEO

I want to thank the entire Nephros team for the tremendous amount of work behind these results, our customers and partners for their continued trust, and our shareholders for their support. With that, I will turn the call over to our CFO, Judy Krandel, for a closer look at the financial results.

Judy KrandelCFO

Thank you, Robert. I will now provide a closer look at Nephros' financial performance for the third quarter and first nine months of 2026. Net revenue for the third quarter was approximately $5.6 million compared with approximately $4.8 million in the third quarter of 2025, an increase of 18%. The increase was driven primarily by growth in product revenue. Our core programmatic revenue increased approximately 8% compared with the prior year quarter. We also experienced significant growth in emergency response revenue and continued growth in service revenue. Cost of goods sold for the third quarter was approximately $2.3 million compared with approximately $1.8 million in the third quarter of 2025, an increase of 26%. Gross margin for the third quarter was approximately 58% compared with 61% during the same period last year.

Judy KrandelCFO

This approximately 3 percentage point decrease was primarily attributable to higher inventory, shipping, and handling costs, including tariff expense, as well as continued growth in service revenue, which currently carries a lower gross margin than our product sales. Selling, general, and administrative expenses were approximately $2.4 million compared with $2.2 million in the third quarter of 2025, an increase of about 9%. The increase was primarily attributable to increased headcount and professional fees. Research and development expense was approximately $331,000 compared with $338,000 in the prior year period, a decrease of about 2%. Depreciation and amortization expenses were approximately $29,000 compared with $34,000 in the third quarter of 2025. Consequently, net income for the third quarter was approximately $500,000 compared with $300,000 during the same period in 2025. Adjusted EBITDA was approximately $600,000 compared with $400,000 in the third quarter of 2025.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day